Why Big Pharma Isn't Scared of Biosimilars

Let's look at how Merck, Johnson & Johnson, Amgen, Hospira, and AbbVie are embracing biosimilars.

Jan 2, 2014 at 10:01AM

he first rule of investing in pharmaceuticals is that when a drug loses patent protection, the drug maker loses sales. Remsima, a biosimilar version of Remicade, has been on sale in Korea since September 2012. Why haven't Remicade sales there fallen off a cliff?

Consider Eli Lilly's Zyprexa. It's not a biologic, but it lost U.S. patent exclusivity in October 2011. During that year, Lilly recorded Zyprexa sales of $2.17 billion in the United States. One year later, that figure fell to just $360 million.

On the other hand, Amgen's (NASDAQ:AMGN) blockbuster biologic, Enbrel, was expected to lose US exclusivity in October 2012, but its exclusivity was extended to 2028. For the first nine months of 2013, Amgen's portion of U.S. Enbrel sales actually increased year-on-year from $2.88 billion to $3.17 billion. Analyst consensus compiled by the Evaluate Group suggests worldwide sales of the biologic will remain at or slightly above present levels for years to come.

Terminology primer
The term biologic gets thrown around a lot because it refers to a lot of different things. In a nutshell, it is an isolated form of something that is created by biological processes and composed of sugars, proteins, nucleic acids, or a combination of the three. Red blood cells, insulin, vaccines, and monoclonal antibodies (MABs) are all considered biologics.

What further separates biologics from small molecule drugs is that their production requires the complex machinery within living cells. Defining steps involve the insertion of a specific DNA sequence into a cell, the culturing of those cells, and the isolation of the biologic from the culture. 

Just because biologics go off patent doesn't mean companies like Johnson & Johnson (NYSE:JNJ) need to invite biosimilar makers to tour its facilities and hand them the cloned cell cultures used to make Remicade. Creating an identical replica of a standard small-molecule drug is relatively simple. Recreating biologics can be far more complicated. Because of this complexity, there is often a slight difference between the original biologic and the replica; this is why they use the term "biosimilar."

What's at stake
In September 2013, the European Medicines Agency (EMA) authorized Celltrion and Hospira's (NYSE:HSP) Inflectra for use in the EU. This is the first biosimilar MAB to hit the European market . It has been granted rights for all eight of infliximab's (Remicade) marketed indications. It should hit big, but so far its reception has been tepid.

In the first nine months of 2013, Johnson & Johnson and Merck (NYSE:MRK) recorded revenue of $4.96 billion and $1.65 billion, respectively. AbbVie's (NYSE:ABBV), Humira, is another MAB that goes off patent in about three years. It's the world's No. 1 drug by sales, and AbbVie relies on it for more than half its revenue.

Dwindling risk-reward ratio
When developing new drugs, companies take a shoot-the-moon approach to capital management. Generics are exactly the opposite. Risks are minimal, but so are the margins. The burgeoning biosimilar industry is finding itself very uncomfortably in the middle.

Regulators, especially in the U.S., are proving to be an enormous hurdle for would-be biosimilar manufacturers. Requiring large, pivotal trials for biosimilars tacks on enough expense to make generic drug companies rethink their strategies. Furthermore, exact requirements are still a bit of a mystery. Motley Fool analyst Brenton Flynn discusses the lack of a viable pathway in this video.

Even if a biosimilar does win approval, a return on investment is still far from certain. In the U.S., the Biologics Price Competition and Innovation Act, a law bundled in with the Affordable Care Act, includes "an extensive process for the innovator biologic and biosimilar manufacturer to litigate patent infringement, validity, and enforceability prior to the approval of the biosimilar." Most importantly, the law demands that makers of biosimilars disclose their complete dossiers during development.

This gives the originator a big advantage. Originators typically file dozens or even hundreds of patents related to the methods and materials used in their manufacturing processes. Seeing the methods used by biosimilar makers and then filing infringement suits could keep worthy biologics from even submitting a biologics license application for years.

Should a biosimilar make it past expensive clinical trials and lengthy patent litigation, it still faces the scrutiny of physicians and patients. If clinical trials and legal fees don't leave biosimilars unable to compete on price, physician and patient perceptions might. Just imagine how much of a discount you would require to inject a drug that is not exactly the same as the one you are used to.

So relax
The big blockbuster biologics will certainly experience some price erosion from biosimilar competition. It's likely that the losses won't be nearly as dramatic as small molecule drugs like Zyprexa, however. Government regulation, physician adoption, and nature all seem to be working against what would otherwise be a burgeoning opportunity for biosimilar specialists like Hospira. For those of you that own companies facing expiration of their biologic patents, you can rest easy for now.

Our top stock for the new year
There’s a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Editor's Note: A previous version of this article had incorrect information regarding patent expirations for Remicade and Enbrel. The Fool regrets the error.

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers